Charles River Laboratories International, Inc. (CRL) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Charles River Laboratories International, Inc. (NYSE:CRL) from a buy rating to a hold rating in a research note released on Monday.

According to Zacks, “Charles River Laboratories is a leading provider of critical research tools and integrated support services that enable innovative and efficient drug discovery and development. Charles River is the global leader in providing the animal research models required in research and development for new drugs, devices and therapies and has been in this business for more than 50 years. “

Other analysts have also recently issued reports about the stock. Barclays PLC reaffirmed a hold rating and set a $102.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 19th. Bank of America Corporation decreased their price target on shares of Charles River Laboratories International from $117.00 to $115.00 and set a buy rating for the company in a research report on Friday, November 10th. Robert W. Baird set a $117.00 price target on shares of Charles River Laboratories International and gave the stock a buy rating in a research report on Monday. BidaskClub raised shares of Charles River Laboratories International from a buy rating to a strong-buy rating in a research report on Tuesday, August 22nd. Finally, ValuEngine cut shares of Charles River Laboratories International from a buy rating to a hold rating in a research report on Friday, November 10th. Seven equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus price target of $106.05.

Shares of Charles River Laboratories International (NYSE:CRL) opened at $101.47 on Monday. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13. Charles River Laboratories International has a 12-month low of $69.51 and a 12-month high of $119.05. The firm has a market cap of $4,756.52, a price-to-earnings ratio of 19.73, a P/E/G ratio of 1.60 and a beta of 0.94.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Thursday, November 9th. The medical research company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Charles River Laboratories International had a net margin of 10.72% and a return on equity of 26.58%. The firm had revenue of $464.23 million during the quarter, compared to analysts’ expectations of $458.93 million. During the same period in the prior year, the company earned $1.18 EPS. The firm’s revenue was up 9.0% on a year-over-year basis. analysts anticipate that Charles River Laboratories International will post 5.13 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by BBNS and is owned by of BBNS. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://baseballnewssource.com/markets/charles-river-laboratories-international-inc-crl-downgraded-by-zacks-investment-research/1781365.html.

In other news, insider Davide Molho sold 6,165 shares of the company’s stock in a transaction dated Thursday, October 5th. The shares were sold at an average price of $110.00, for a total value of $678,150.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Bradley Nixon Scharfe sold 1,000,000 shares of the company’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $0.27, for a total transaction of $270,000.00. Over the last three months, insiders acquired 10,500 shares of company stock valued at $2,885 and sold 1,012,147 shares valued at $1,591,514. Corporate insiders own 2.20% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Bridgewater Associates LP acquired a new stake in shares of Charles River Laboratories International in the 2nd quarter valued at about $679,000. Prudential Financial Inc. raised its stake in shares of Charles River Laboratories International by 19.0% in the 2nd quarter. Prudential Financial Inc. now owns 425,860 shares of the medical research company’s stock valued at $43,076,000 after purchasing an additional 68,058 shares in the last quarter. American Century Companies Inc. acquired a new stake in shares of Charles River Laboratories International in the 2nd quarter valued at about $292,000. Northern Trust Corp raised its stake in shares of Charles River Laboratories International by 1.5% in the 2nd quarter. Northern Trust Corp now owns 436,860 shares of the medical research company’s stock valued at $44,188,000 after purchasing an additional 6,304 shares in the last quarter. Finally, Alps Advisors Inc. raised its stake in shares of Charles River Laboratories International by 0.3% in the 2nd quarter. Alps Advisors Inc. now owns 5,350 shares of the medical research company’s stock valued at $541,000 after purchasing an additional 14 shares in the last quarter. Institutional investors and hedge funds own 97.46% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Get a free copy of the Zacks research report on Charles River Laboratories International (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.